HemaCare Corp. to Trade On OTC Bulletin Board

Business Wire, Nov 2, 1998

LOS ANGELES--(BUSINESS WIRE)--Nov. 2, 1998--HemaCare Corp. announced today that, effective Oct. 30, 1998, its shares will no longer trade on the Nasdaq's SmallCap Market because the bid price for its shares has fallen below the $1.00 per share Nasdaq minimum listing maintenance requirement.

The company's stock now qualifies to trade on the OTC Bulletin Board under the symbol "HEMA".

According to HemaCare's Chairman, Alan C. Darlington, "The company's Board of Directors and management do not believe that the trading price of its stock reflects the value of the company."

Darlington continued, "The company is quickly integrating the recently acquired assets of Coral Therapeutics Inc. ("Coral"), an East Coast based provider of blood services. The Coral acquisition demonstrates the company's commitment to creating shareholder value."

CORPORATE BACKGROUND

HemaCare has been a leading provider of blood products and services since its inception in 1978. The company's national operations are focused on providing blood services and products to hospitals and hospital groups.

This news release contains "forward-looking statements" within the meaning of the term in the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Additional written or oral forward-looking statements may be made by the company from time to time in filings with the Securities and Exchange commission or otherwise. Statements contained herein that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions referenced above. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements contained herein.

Note to editors: Visit HemaCare's Investor Relations site at

http://www.businesswire.com/cnn/hema.htm